StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report issued on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm decreased their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, September 23rd.

Aptevo Therapeutics Price Performance

NASDAQ APVO opened at $0.28 on Friday. The stock’s 50 day moving average is $0.23 and its 200 day moving average is $0.39. Aptevo Therapeutics has a 12 month low of $0.14 and a 12 month high of $10.80.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.